Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q3 2016 call → NOWe need to determine if management explains where the company's business is going by narrating what its counterparties are themselves doing and scaling. The key is whether management's forward account is substantially about the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, etc., that the company already supplies, and that this is presented as the driver of the company's coming volume. Let's analyze the transcript. Management discusses several initiatives. For example, the Viper program: they mention a follow-on order for $2.2 million received in early Q4, with deliveries starting in Q4. They talk about the end-users receiving the product well, and that there could be an ongoing tail. But is this narrating the counterparty's own trajectory? They mention the U.S. Army's Soldier Radio Waveform radio appliqué requirements through a prime OEM. They say "We're hopeful that this could lead to an ongoing stream of future orders." That is more about hope and potential, not a clear description of the counterparty's own ramp. They also mention "the feeling of the Rifleman Radio" and that "end-users are receiving the product well" but that's not a detailed account of the counterparty's expansion. For the medical business, they mention a $4.8 million blanket order from an existing customer, but that's just an order, not a description of the customer's own growth trajectory. They mention Accutronics winning a development contract for a high-end digital x-ray application with shipments expected to begin Q3 2017, potentially valued up to $1.5 million. That is a specific customer program, but it's a development contract, and the value is relatively small. They also mention a major global medical devices manufacturer relationship that started with initial contact and has grown into seven new development activities. But again, that's about development activities, not a clear ramp of the counterparty's own expansion.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.